Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Endocrinology
•
Thyroid Disorders
What specific features in a patient with euthyroid MNG increase their risk of developing functional autonomy and overt hyperthyroidism?
Related Questions
What work up do you recommend for persistent subclinical hyperthyroidism with decreased RAI uptake and negative thyroid antibody tests?
For patients with central hypothyroidism and a clear etiology (such as recent head irradiation), do you recommend brain imaging prior to starting thyroid hormone replacement therapy?
Can you explain the block and replace approach in the treatment of thyrotoxicosis, including when it is most appropriate to use and how it compares to other treatment options?
What is the clinical significance of positive anti-thyroid antibodies in a patient that is post-thyroidectomy?
What are the clinical indications and expected outcomes of radiofrequency ablation therapy for benign thyroid nodules?
Are thyroid molecular tests (such as Afirma, ThyroSeq) validated for use on FNA thyroid nodule samples that are not Bethesda class 3-4?
Is there a maximum duration for raloxifene use?
Do progesterone only oral contraceptive pills affect cortisol binding globulin?
Should we aim to reduce or stop thiazides in patients with thiazide-induced hypercalcemia given its similar risk profile to untreated primary hyperparathyroidism?
How many days prior to surgery do you recommend stopping SGLT2 inhibitors and when is it safe to resume therapy?
